Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
Kyverna presented updated Phase 1 data on miv-cel in progressive multiple sclerosis at the joint ACTRIMS-ECTRIMS meeting in Toronto, showing all five evaluable patients with stable or improved EDSS disability scores. Four patients with over a year of follow-up sustained improvement without chronic immunotherapies, the first treated patient has durable benefit beyond two years, and safety was clean with no high-grade CRS and no ICANS or IEC-HS cases. Miv-cel also received an RMAT designation for non-active secondary progressive MS -- its third -- with a development strategy update expected by early 2027.
Key figures
- Drug Name
- miv-cel (mivocabtagene autoleucel, KYV-101)
- Phase Of Trial
- Phase 1
- Doses tested
- ["33M","100M"]
- Patients treated
- 6
- Longest follow up
- beyond two years
- Rmat designations
- ["stiff person syndrome (SPS)","generalized myasthenia gravis (gMG)","non-active secondary progressive multiple sclerosis (naSPMS)"]
- Patients treated to date
- more than 100
- Patients with efficacy data
- 5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.